July 17 (Reuters) - Abbott ABT.N beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.
Continuous glucose monitor makers such as Abbott, Dexcom DXCM.O and Medtronic MDT.N are riding a surge in demand as diabetes awareness rises, insurance coverage expands, and patients embrace finger-prick-free technology.
On an adjusted basis, the company reported a profit of $1.26 per share for the second quarter, compared with analysts' average estimate of $1.25, according to data compiled by LSEG.
Abbott's quarterly revenue came in at $11.1 billion, in line with expectations.
The medical device business, which sells diabetes and heart-related devices among others, posted sales of $5.37 billion, topping estimates of $5.24 billion.
Abbott said on Thursday it planned to build a manufacturing facility in the U.S state of Georgia by 2028 to support its cardiovascular business.
This adds to April announcements for manufacturing and research projects in Illinois and Texas, which are expected to go live by the end of the year, and help Abbott mitigate any likely impact from President Donald Trump's tariffs.
(Reporting by Puyaan Singh and Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。